Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - AccuredReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Crinetics Pharmaceuticals (CRNX) Receivables - Net (2025)

Crinetics Pharmaceuticals has reported Receivables - Net over the past 1 years, most recently at $592000.0 for Q4 2025.

  • For Q4 2025, Receivables - Net changed N/A year-over-year to $592000.0; the TTM value through Dec 2025 reached $592000.0, changed N/A, while the annual FY2025 figure was $592000.0, N/A changed from the prior year.
  • Receivables - Net for Q4 2025 was $592000.0 at Crinetics Pharmaceuticals.
  • Over five years, Receivables - Net peaked at $592000.0 in Q4 2025 and troughed at $592000.0 in Q4 2025.